Bio-Techne (TECH) Receives a Buy from Leerink Partners

Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $48.10.

Stay Ahead of the Market:

According to TipRanks, Souda is an analyst with an average return of -14.5% and a 26.87% success rate. Souda covers the Healthcare sector, focusing on stocks such as Illumina, Bruker, and Repligen.

Currently, the analyst consensus on Bio-Techne is a Moderate Buy with an average price target of $82.00.

TECH market cap is currently $7.9B and has a P/E ratio of 50.79.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TECH in relation to earlier this year. Most recently, in February 2025, Amy E. Herr, a Director at TECH sold 1,860.00 shares for a total of $122,685.60.